Introduction
============

Influenza virus is one of the leading causes of viral disease resulting in widespread morbidity, a large number of lives lost and substantial economic loss. During annual influenza outbreaks, an estimated 5%--15% of the world's population is infected causing an estimated one million deaths every year ([@b116-copd-2-229]; [@b127-copd-2-229]). Moreover, we are currently facing a potential new pandemic that could cause unprecedented levels of global morbidity and mortality, particularly in the developing countries but also in the industrialized world. Today's inactivated influenza vaccines provide satisfactory protection against seasonal influenza in healthy adults ([@b5-copd-2-229]; [@b118-copd-2-229]) and annual vaccination is cost effective ([@b70-copd-2-229]). However, there is still room for improvement in current vaccines, especially in the elderly "at risk" groups where vaccine efficacy is not optimal. Two classes of antiviral agents are also licensed for therapeutic and prophylactic use against influenza, complementing but not replacing, the use of influenza vaccines (Reviewed in [@b75-copd-2-229]).

In man, influenza virus is transmitted via droplets expelled upon coughing and sneezing and normally infects the epithelial cells of the upper respiratory tract ([@b73-copd-2-229]). The incubation period is usually 2--3 days, but can be as long as 7 days. The patient is generally contagious during the febrile phase, but cases of viral spread have been observed prior to the onset of symptoms ([@b73-copd-2-229]). The duration of illness is usually one week and is normally accompanied by high fever, headache, myalgia, sore throat and rhinitis. People with low levels of viral shedding often have fewer clinical symptoms or are asymptomatic ([@b65-copd-2-229]; [@b66-copd-2-229]).

Healthy people usually recover within one week of illness without requiring any medical intervention. In the very young, the elderly and people with underlying medical problems (eg, chronic obstructive pulmonary disease (COPD), diabetes, cancer, heart disease) influenza poses a serious risk, and infection may lead to hospitalization and in some cases death ([@b67-copd-2-229]). Frequently, the cause of hospitalization or death is viral pneumonia or secondary bacterial pneumonia. Substantial levels of community morbidity occur during an influenza outbreak, resulting in a significant strain on the health care system. The economic burden of influenza on society can also be significant. In the USA alone, a conservative estimate predicted an annual loss of 12--17 billion dollars ([@b120-copd-2-229]; [@b118-copd-2-229]).

Respiratory tract infections such as influenza often lead to exacerbation of disease in COPD patients. Influenza infection in such patients requires increased medical intervention and serious complications can result in hospitalization and death ([@b126-copd-2-229]). Each exacerbation in COPD patients leads to a progressive irreversible decrease in lung function, the frequency and severity of the exacerbations increases as the disease worsens ([@b74-copd-2-229]). The patient's quality of life therefore deteriorates with an increased need for hospitalization. Importantly, influenza is a vaccine preventable disease and this review will focus on influenza virus and prophylaxis with inactivated influenza vaccines in "at risk" groups, herein COPD patients.

The influenza virus and its life cycle
======================================

Influenza belongs to the family of *Orthomyxoviridae* ([@b26-copd-2-229]). There are three types of influenza, A, B and C, which are classified on the basis of antigenic differences in the internal proteins (nucleoprotein (NP) and matrix (M1) protein). Influenza A and B viruses are important human pathogens, whereas influenza C infection results only in a mild respiratory infection in man and will not be discussed further in this review. The influenza A genus is further subdivided based on the antigenic properties of its surface glycoproteins, the haemagglutinin (HA or H) and the neuraminidase (NA or N). Currently, there are 16 HA and 9 NA subtypes recognized by the WHO ([@b118-copd-2-229]) and of these the H3N2 and H1N1 subtypes are circulating widely in man today.

Influenza virus has a negative sense, segmented, single stranded (ss) RNA genome. The genome of influenza A virus has 8 segments, each coding for one or two proteins, in all a total of 11 proteins (Table [1](#t1-copd-2-229){ref-type="table"}). Each segment is encapsulated by the NP to form a ribonucleoprotein complex (RNP). Bound to each RNP, is the viral RNA polymerase complex, consisting of the three viral gene products (PB1, PB2, PA) (Figure [1](#f1-copd-2-229){ref-type="fig"}). Three viral proteins are found in the viral envelope of influenza A virus; the HA, NA and the ion channel protein M2. The M1 protein lines the viral envelope in close proximity to the RNP and is hypothesized to interact with the cytoplasmic tails of the surface glycoproteins ([@b59-copd-2-229]). The virion is pleomorphic in structure, the main form is a spherical particle (80--120 nm in diameter), but also filamentous and bean-like structures are found.

The HA and NA are the major antigenic proteins of the virus. Most antibodies produced are directed against these proteins and they will be briefly discussed here. The HA is a trimeric protein, composed of three identical monomers, which must be post-translationally cleaved by cellular proteases in order to be functional ([@b17-copd-2-229]). The distal tip of HA contains the receptor binding sites and the transmembrane stalk attaches the HA to the viral envelope (Figure [1](#f1-copd-2-229){ref-type="fig"}). NA is a tetramer with a mushroom shape and contains the viral enzyme (neuraminidase), which is responsible for release of newly assembled virus from the cell. The antiviral drugs Oseltamivir and Zanamivir bind to the enzymatic site of NA, reducing or hindering the release of new virus.

Influenza virus replicates in the epithelial cells lining the respiratory tract. The enzymatic activity of NA helps the virus in navigating through the mucus layer and upon cell contact allows the HA to attach to the sialic acid containing host cell receptor. The virus particle is then engulfed and taken up into the cell in a vesicle (endosome) in a process called receptor-mediated endocytosis ([@b59-copd-2-229]). The low pH initiates a conformational change in the HA molecule facilitating a fusion with the endosomal membrane. At the same time the M2 ion channel protein lowers the pH inside the virion, so that the RNPs become disassociated from M1, allowing the RNPs to enter the cytosol. The M2 protein is the target for the influenza antiviral drugs Amantadine and imantadine ([@b75-copd-2-229]).

The RNPs migrate to the nucleus and the viral polymerase complex transcribes and replicates the viral RNA to form new viral RNA and mRNA. The NP and the M1 are translated in the cytosol, before they migrate to the nucleus to take part in the RNP assembly and transport. Viral proteins, possibly NP, may regulate the switch between transcription and replication ([@b85-copd-2-229]). New viral genomes are encapsidated by NP and migrate to the cytosol. The HA, NA and the M2 proteins are translated on the endoplasmatic reticulum and transported to the cell membrane. M1 and RNPs interact with the cytoplasmic tails of HA and NA at the cell membrane. The M1 protein further interacts with cellular proteins and is involved in determining both the virion shape and size, as well as being involved in the viral budding process ([@b59-copd-2-229]; [@b51-copd-2-229]). The virus is then released by budding from the cell surface membrane, which is facilitated by the NA.

Influenza ecology
=================

Influenza A viruses infect a wide range of species such as birds, seals, horses, man and pigs ([@b66-copd-2-229]). In contrast, influenza B viruses are mainly found in man. The natural reservoir for influenza A viruses is birds, with waterfowl being the most important host and will, for the foreseeable future, continue to be a threat to human health ([@b113-copd-2-229]; [@b66-copd-2-229]). The virus may spread from this reservoir to other species including man (Figure [2](#f2-copd-2-229){ref-type="fig"}). Normally, avian influenza is a mild or asymptomatic intestinal infection in birds and the virus may be secreted in high titers through the cloacae for a period up to 30 days ([@b46-copd-2-229]). The practice in many parts of the world of keeping free-ranging poultry close to the family dwelling, allowing both exchange of avian influenza with wild birds as well as facilitating zoonoses, is considered to be unsafe (reviewed in [@b112-copd-2-229]).

The receptor binding specificity of the surface glycoprotein HA is an important determinant of host range. Only one amino acid substitution in HA (226Leu→Gln) may change the receptor specificity of HA ([@b25-copd-2-229]), shifting from human (SAα-(2, 6)Gal) to avian (SAα-(2, 3)Gal) receptor preference. Humans also express a low level of the avian receptor (SAα-(2, 3)Gal) in the lower respiratory tract, which may explain why avian influenza virus only rarely infects man ([@b95-copd-2-229]). In addition to the HA gene, the pathogenicity of influenza is also determined by a number of gene segments including the polymerase complex, the NS1 and the NA ([@b34-copd-2-229]; [@b2-copd-2-229]; [@b106-copd-2-229]).

Influenza epidemiology
======================

The annual influenza outbreaks usually start during the winter months in temperate climates. In contrast, in the tropics and subtropics influenza virus may be isolated throughout the year. The number of suspected influenza cases, designated influenza like illness (ILI), is a frequently used as a measure of epidemic activity ([@b28-copd-2-229]; [@b101-copd-2-229]). However, there is more than one case definition of ILI used. The WHO defines ILI as a sudden onset of fever (\>38 °C), cough or sore throat in the absence of other diagnoses ([@b114-copd-2-229]), whereas others have used a sudden onset of fever, cough and fatigue ([@b107-copd-2-229]), or fever as well as least two of the following symptoms: headache, cough, sore throat and myalgia ([@b6-copd-2-229]). Generally, influenza A H3N2 normally results in the most serious illness, B viruses intermediate and influenza A H1N1 cases present with the mildest manifestations ([@b63-copd-2-229]). Influenza A viruses are normally responsible for four-fold more hospitalizations than influenza B viruses ([@b66-copd-2-229]).

Influenza related deaths are frequently under-reported because influenza often exacerbates underlying disease, which may be recorded as the primary cause of death ([@b73-copd-2-229]). The number of influenza related deaths is therefore often monitored as the number of excess deaths compared to a period without (known) influenza activity. Influenza mortality usually occurs in the "at risk" groups; people with underlying chronic medical conditions like COPD, diabetes, cancer and heart disease as well as in the elderly. Influenza related deaths worldwide are estimated to be about 1 million people each year ([@b116-copd-2-229]; [@b127-copd-2-229]) and in the USA about 60%--70% of deaths occur in people over 65 years old ([@b82-copd-2-229]). However, the true number of influenza related deaths worldwide is difficult to estimate, since most epidemiological data are derived from industrialized countries in the temperate zone ([@b118-copd-2-229]).

Antigenic drift of influenza
============================

Influenza is an RNA virus and as such has a high frequency of copy errors during replication due to a lack of proof-reading by the polymerase. This results in substitutions in the genome at a rate that is many-fold higher than that found for DNA viruses ([@b24-copd-2-229]).

The accumulation of mutations, particularly in the HA, may lead to changes in the antigenic signature of the virus allowing the virus to escape herd immunity and cause new outbreaks, a process called antigenic drift ([@b66-copd-2-229]). Influenza A viruses mutate more frequently than influenza B viruses and hence influenza B is more antigenically stable ([@b125-copd-2-229]). The slower evolution of influenza B viruses may be attributed to a longer co-evolution in man and host specific adaptations ([@b113-copd-2-229]). The risk of reassorting with avian subtypes makes influenza A virus a particularly dangerous infectious agent for man.

Antigenic shift of influenza
============================

During the 20th century there were three pandemics, namely in 1918, 1957 and 1968 ([@b118-copd-2-229]). The term pandemic is only used when an antigenic shift occurs and the novel influenza A subtype infects humans causing global widespread outbreaks resulting in substantial morbidity and mortality. The 1918 pandemic had the highest mortality rates of the 20th century pandemics, causing approximately 40 million deaths worldwide, with an unprecedented number of deaths in young adults (review in [@b90-copd-2-229]).

Antigenic shift may occur after reassortment of viral genome segments from two different influenza A subtypes. When two viruses co-infect the same cell and exchange segments, a novel reassorted virus with new combinations of HA and NA surface glycoproteins may be generated. When a virus with a novel HA (and NA) spreads efficiently in man, the virus may cause a pandemic ([@b113-copd-2-229]). These novel influenza A viruses cross the species barrier from the large avian reservoir and can strike at unpredictable intervals. Pigs, having receptors for both the human and avian influenza viruses, and are thought to play a role as a "mixing vessel" producing new reassortments of influenza A virus (see Figure [2](#f2-copd-2-229){ref-type="fig"}). The pandemics of 1957 and 1968 were the result of a reassortment between avian and human influenza viruses, possibly in pigs ([@b113-copd-2-229]).

An antigenic shift can also occur after direct transfer of an avian virus into man. The H1N1 virus responsible for the 1918 pandemic was not a reassortant, but was transmitted to man *in toto* from an avian source ([@b106-copd-2-229]). The zoonotic cases of avian H5N1 in Hong Kong in 1997 and the ongoing zoonosis of H5N1 demonstrate that avian viruses can directly infect man and do not necessarily require a "mixing vessel" ([@b102-copd-2-229]; [@b15-copd-2-229]). In fact, the genetic reassortment between avian and human subtypes could well take place in man. However, to date there has not been an adaptation of this novel H5N1 subtype to allow a sustained human-to-human spread.

Vaccines and immunity
=====================

The two main types of influenza vaccine are inactivated virus, which is by far the most commonly used, and live virus vaccines. Inactivated vaccines are normally administered parenterally. In contrast, live virus vaccines are administered intranasally with an attenuated virus to produce a limited upper respiratory tract infection without causing any overt clinical illness. However, live influenza vaccines are not licensed outside Russia and the USA. In the USA, live vaccines are so far only recommended for healthy subjects 5--49 years old, thus excluding their use in COPD patients ([@b43-copd-2-229]).

Current inactivated influenza vaccines are trivalent containing strains from two influenza A subtypes (H1N1 and H3N2) and one influenza B variant. The vaccine is normally administered during October and November in the northern hemisphere. A single-dose regime is mostly used, but for preschool children two doses are recommended at one-months intervals. The vaccine strains need to be epidemiologically relevant, and the WHO updates their strain recommendation on an annual basis for each hemisphere. The selected strains are either reassorted with a high-growth laboratory strain or adapted to give better yields in embryonated eggs. The reassorted strain expresses the desired HA and NA of the field virus, while maintaing the high growth potential in eggs ([@b58-copd-2-229]). Embryonated hens' eggs are the most commonly used vaccine substrate. However, some vaccine manufacturers are now licensing their cell culture based vaccines. This will give the vaccine industry greater flexibility and allow scaling up their production if a sudden surge in demand should occur.

Formulation of inactivated vaccines
===================================

There are three main formulations of inactivated vaccines (extensively reviewed in [@b30-copd-2-229]). Whole virus vaccine is inactivated by chemical agents (eg, formaldehyde or β-propiolactone) in a procedure that does not destroy the viral envelope ([@b31-copd-2-229]). This type of vaccine was widely utilized until the end of the 1970s, but its use was largely discontinued due to a somewhat higher frequency of side reactions ([@b1-copd-2-229]; [@b7-copd-2-229]; [@b37-copd-2-229]; [@b45-copd-2-229], [@b44-copd-2-229]). A split virus vaccine is produced using chemical agents (eg, ether or tributyl phosphate) to disrupt the viral envelope ([@b20-copd-2-229]; [@b1-copd-2-229]). Immunization with split virus vaccine produces fewer side reactions (ie, has a lower reactogenicity), but has also a somewhat reduced immunogenicity compared to whole virus vaccine ([@b1-copd-2-229]; [@b37-copd-2-229]). A third vaccine formulation, the subunit type, consists of highly purified surface antigens, HA and NA, and is the least reactogenic influenza vaccine on the market today ([@b87-copd-2-229]). All inactivated vaccines are administered parenterally, either intramuscularly or deep subcutaneously. However, more recent studies using highly purified virus have found that split and whole virus vaccine induce similar levels of side reactions ([@b45-copd-2-229]; [@b44-copd-2-229]).

The normal adult human dose is standardized to a concentration of 15 μg HA per strain, and thus the trivalent vaccine contains a total of 45 μg of HA. Current influenza vaccines are not adjuvanted, the use of adjuvants may be necessary for pandemic vaccines based on avian influenza viruses where the vaccine recipient would be immunologically naïve ([@b100-copd-2-229]).

Immunity after vaccination
==========================

Humans have generally experienced a number of influenza infections, which prime the immune system and create an immunological memory ([@b97-copd-2-229]; [@b80-copd-2-229]; [@b104-copd-2-229]). Upon vaccination with inactivated vaccine, reactivation of immunological memory results in production of mainly IgG as well as some IgA antibodies ([@b9-copd-2-229]; [@b10-copd-2-229]; [@b18-copd-2-229]; [@b41-copd-2-229]). In contrast, after a natural infection the immune response will elicit more IgA antibodies and a cellular T-cell response ([@b5-copd-2-229]). If there is no pre-existing immunity (for example in children), two doses of vaccine are recommended given at least one month apart to achieve a satisfactory immune response ([@b43-copd-2-229]). It is likely that a two dose regime will be required for a pandemic vaccine containing a novel influenza subtype, in addition to the use of an adjuvanted formulation ([@b98-copd-2-229]; [@b44-copd-2-229]).

The systemic response after vaccination is rapid in healthy subjects with the antibody secreting cell response peaking after one week, while the serum antibody continues to increase up to 2--3 weeks after vaccination ([@b19-copd-2-229]). The concentration of influenza-specific serum antibody then wanes over time, but remains elevated at least 8 months post vaccination ([@b16-copd-2-229]). The importance of serum antibody is shown by the fact that the higher the serum antibody level, the less likely the person is to experience clinical illness upon subsequent infection ([@b47-copd-2-229]; [@b57-copd-2-229]). Passively derived serum IgG probably leaks through the infected epithelial cell layer and neutralizes the virus and thus prevents binding to the cellular receptor ([@b104-copd-2-229]). IgG diffuses more readily across the alveolar wall in the lower respiratory tract than across the epithelial cells in the upper airways ([@b64-copd-2-229]), which makes IgG antibodies particularly important in avoiding the most serious complications of infection.

COPD patients have a damaged epithelial cell layer and it has been shown in experimental models for asthma and chronic bronchitis, a lasting change in the airway epithelium and smooth muscle behavior after viral infection ([@b48-copd-2-229]). These authors have hypothesized a viral cause of both acute and chronic manifestations of asthma and chronic bronchitis. Studies in healthy individuals and animal models have shown apoptosis of cells in the epithelial cell layer and the resulting inflammation also attract effector cells to the site of infection causing further cell death ([@b11-copd-2-229]). This could have consequences also for the immune response in the damaged lungs of COPD sufferers, but no study to date has adequately addressed this issue. A thorough review of the aetiology of exacerbations in COPD sufferers has recently been published ([@b94-copd-2-229]).

Immunity after influenza infection
==================================

Initially, influenza virus replicates in the epithelial cells of the respiratory tract and this is also an important site for the immune response ([@b104-copd-2-229]). IgA is actively transported in its secretory form, S-IgA, across the epithelial surfaces of the respiratory tract and neutralizes virus by binding to its surface proteins. Once the infection is established, a cytotoxic response is induced, often against the internal viral proteins, and is involved in viral clearance and recovery from infection ([@b93-copd-2-229]; [@b103-copd-2-229]). The internal influenza proteins are more conserved than HA and NA, thus memory T-cells may be more cross-reactive against drifted viruses and possibly across influenza A subtypes.

Infection-induced immunity is thought to be long-lived, but will more or less become redundant due to the continuous antigenic changes of the virus. A special case was demonstrated when the H1N1 virus re-appeared in 1977, which had circulated 20 years earlier ([@b23-copd-2-229]). Before the first H1N1 wave, antibodies were only detected in people that were in their childhood in the 1950s and not in older or younger individuals ([@b52-copd-2-229]). The long-lived immune response to influenza virus experienced in early childhood is often referred to as 'Antigenic Sin' ([@b29-copd-2-229]). During the first wave, people under the age of 20 were almost exclusively infected ([@b86-copd-2-229]) and they also had a marked lower immune response to inactivated vaccines containing H1N1, suggesting that they did not have any immunological memory against this virus ([@b97-copd-2-229]). The 1977 virus was antigenically very similar to a 1950 isolate and was possibly inadvertently released into the human population ([@b79-copd-2-229]).

Target groups for vaccination
=============================

The WHO has issued a priority list of groups, which should be annually vaccinated (Listed in full in Table [2](#t2-copd-2-229){ref-type="table"} ([@b118-copd-2-229])). These groups are: (1) Residents of institutions for the elderly or the disabled; (2) Elderly non-institutionalized individuals with certain chronic medical conditions; (3) Other individuals in the community with certain chronic medical conditions; (4) Individuals who are above a nationally defined age limit; and (5) Other groups defined on the basis of national data such as those with frequent contact with high-risk persons, health care workers, pregnant women and children age 6--23 months old. The WHO has to date not issued any recommendations on the use of live influenza vaccines ([@b118-copd-2-229]).

Since influenza strains are prone to drift antigenically from one influenza season to the next, annual vaccination is recommended. Repeated influenza vaccination does not compromise the immune response, and should therefore not be used as an argument against annual vaccination ([@b56-copd-2-229]; [@b4-copd-2-229]).

Safety of inactivated influenza vaccines
========================================

More than 300 million doses of influenza vaccines are administered each year and the vaccine has an excellent safety record ([@b5-copd-2-229]). Local side reactions usually occur in 15%--20% of the vaccinees, most commonly pain and redness at the injection site ([@b118-copd-2-229]). Transient and mild systemic reactions can also occur and include low-grade fever and headache, especially in children, but generally do not interfere with daily activities ([@b121-copd-2-229]).

Most people can be vaccinated without any complications. However, children younger than 6 months and people with known allergies to egg protein are advised against vaccination, whereas persons with an acute febrile illness should just postpone their vaccination until they have recovered ([@b121-copd-2-229]; [@b118-copd-2-229]). However, a mild febrile illness is not considered a contraindication to vaccination ([@b43-copd-2-229]).

Influenza vaccination is recommended for a number of groups with underlying medical conditions and there is considerable information on the vaccine's safety in these patients. A good safety record has been observed using inactivated influenza vaccines in patients with COPD ([@b49-copd-2-229]; [@b84-copd-2-229]; [@b122-copd-2-229]) In adults with asthma there is a very low incidence of clinically significant adverse reactions, for example, out of 40 million vaccine doses administered to such patients, only 5 cases of asthma exacerbations were reported over a ten-year period ([@b78-copd-2-229]). In asthmatic patients on oral steroid therapy, no serious local or systemic side reactions were reported after vaccination with an inactivated influenza vaccine ([@b81-copd-2-229]).

Influenza vaccination will of course only protect against illness caused by influenza virus and not by other acute respiratory infections as shown in a recent study where the incidences of respiratory illnesses over a year was not affected by influenza vaccination ([@b122-copd-2-229]). This is to be expected as, at least in the temperate zone, influenza normally is only epidemic for a few months each year. About 30% of exacerbations of COPD are caused by viral pathogens, and of these less than half are caused by influenza ([@b54-copd-2-229]; [@b12-copd-2-229]). Even so, influenza vaccination clearly reduced the frequency of exacerbations in COPD cohorts ([@b84-copd-2-229]). Some COPD patients occasionally report a worsening of their condition immediately following vaccination. However, in a recent study no increased usage of corticosteroids was found after vaccination ([@b105-copd-2-229]). People with asthma and COPD are considered to be one of the groups that benefit most from influenza vaccination, consequently they are included in the "at risk" groups by the WHO ([@b115-copd-2-229], [@b118-copd-2-229]).

Vaccine efficacy: measurement and contributing factors
======================================================

The protection elicited by influenza vaccine is notoriously difficult to quantify. The term vaccine efficacy refers to well-controlled experiments with a placebo control group ([@b42-copd-2-229]) and sometimes involves young study subjects with a better than average health. Vaccine effectiveness is used to describe the protective effect of the vaccine when used as a part of a public health scheme and can be considerably lower than the efficacy. Both vaccine effectiveness and efficacy are highly dependent upon the specific outcome being measured, the degree of antigenic match between epidemic virus in circulation and the vaccine strain, as well as the severity of the epidemic. However, the vaccine efficacy, especially when measured by serological correlates of protection, may be an underestimate of the true effect of vaccination, partly because little data is available on the number of vaccinees who undergo a sub-clinical influenza infection ([@b76-copd-2-229]).

Vaccine efficacy is commonly measured using surrogate correlates of protection. The serum antibody response is often tested by the haemagglutination inhibition (HI) assay ([@b47-copd-2-229]; [@b57-copd-2-229]). An HI titer ≥40 indicates a 50% protective level against influenza ([@b47-copd-2-229]; [@b57-copd-2-229]). The level of seroprotection, ie, the percentage of vaccinees that have an HI titer after vaccination of at least 40, was found in a meta-study of mainly young health subjects under 65, to be 80%--90% (Table [3](#t3-copd-2-229){ref-type="table"}) ([@b5-copd-2-229]). Vaccination with inactivated influenza vaccine has been shown to prevent laboratory confirmed influenza in 70%--90% of healthy adults ([@b92-copd-2-229]; [@b119-copd-2-229]; [@b8-copd-2-229]; [@b5-copd-2-229]; [@b55-copd-2-229]; [@b43-copd-2-229]; [@b118-copd-2-229]). The vaccine efficacy is reduced if a more general clinical outcome is measured, for instance one study showed only a 25% reduction in upper respiratory tract illness and a 43% reduction in absenteeism from work ([@b70-copd-2-229]).

A significant factor when evaluating the efficacy of the vaccine is the antigenic match between the vaccine strains and the circulating influenza viruses in the community. Normally, the antigenic difference between them is trivial, but occasionally there is a mismatch. Due to the poorer immune response in the elderly, this may be more important in this group than in healthy adults ([@b21-copd-2-229]). In healthy subjects, however, the vaccine is effective (49%--53%) in preventing illness also in years with a sub-optimal match between the vaccine and circulating influenza strains ([@b89-copd-2-229]; [@b91-copd-2-229]). The level of circulating influenza in the community also complicates the calculation of the effectiveness of the vaccine. In years of high influenza activity and widespread outbreaks, the vaccine will show a higher efficacy ([@b53-copd-2-229]) and better cost/benefit ratio ([@b72-copd-2-229]; [@b108-copd-2-229]).

Efficacy and effectiveness in "at risk" populations
===================================================

The immune response elicited after influenza vaccination in the elderly is poorer than in younger subjects (Table [3](#t3-copd-2-229){ref-type="table"}) ([@b77-copd-2-229]), which is important for COPD patients as they are often at an advanced age ([@b109-copd-2-229]). This is reflected in the influenza vaccine licensing criteria in the EU, which have less stringent requirements for the vaccine's immunogenicity in subjects over 60 years of age ([@b14-copd-2-229]). In older patients (\>65), a lower number of subjects elicits an increase in serum antibody after vaccination than in healthy adults, and the seroprotection rate was generally 40%--70% ([@b40-copd-2-229]; [@b62-copd-2-229]; [@b77-copd-2-229]; [@b35-copd-2-229]; [@b61-copd-2-229]). Similar findings were observed in a trial with COPD patients with 45%--87% achieving a protective HI titer ([@b122-copd-2-229]). However, institutionalized elderly and infirm subjects often have a particularly poor response after vaccination ([@b39-copd-2-229]). For ethical reasons few case-control studies have been undertaken investigating the efficacy of inactivated vaccines in the "at risk" groups.

A much used marker for measuring vaccine efficacy is the prevention of ILI. Some ILI cases are not due to influenza virus, but other respiratory pathogens and the vaccine efficacy in the elderly and probably also COPD sufferers against ILI is relatively low (35%) ([@b110-copd-2-229]). The positive predictive value of ILI actually being due to influenza is 23%--60%, and is very dependent on the case definition ([@b107-copd-2-229]). The study conducted by Wongsurakiat et al showed a significant reduction (66%) in the number of ILI cases between vaccinated and unvaccinated COPD patients, despite a small patient group size ([@b122-copd-2-229]). Using a more specific influenza diagnosis, namely laboratory confirmed influenza, the vaccine had a 58% efficacy in healthy elderly subjects ([@b35-copd-2-229]). This is similar to the reduction of laboratory confirmed influenza observed in adults 16--64 years old ([@b55-copd-2-229]).

During the influenza season there is an increase of hospitalization of COPD patients, clearly demonstrating the impact influenza illness can have on this group of patients ([@b126-copd-2-229]). Influenza vaccination, however, only partly protects this group against hospitalization for pneumonia and influenza (P&I) as there are several causes not related to influenza for P&I. Several studies in the elderly population, found the reduction in hospitalization for P&I to be significant after influenza vaccination (33%--52%) ([@b38-copd-2-229]; [@b71-copd-2-229]; [@b110-copd-2-229]). There is an rapid deterioration in the quality of life with increasing number of COPD exacerbations ([@b74-copd-2-229]) and influenza vaccine has been shown to have a 75%--80% effectiveness in reduction of acute respiratory illnesses, independently of the severity of COPD (mild, moderate and severe) ([@b49-copd-2-229]; [@b122-copd-2-229]).

Older people may not fully recover after an influenza infection and thus one significant consequence of hospitalization may be permanent disability ([@b60-copd-2-229]). Influenza vaccination reduced the hospitalization rate by 52% in elderly patients with chronic lung disease ([@b69-copd-2-229]). An additional strategy for protecting these residents is therefore vaccination of the nursing-home staff caring for them ([@b88-copd-2-229]). Vaccination of family members and other close contacts will therefore indirectly protect the "at risk" groups ([@b83-copd-2-229]) and is a policy that is advocated by the WHO ([@b118-copd-2-229]).

The efficacy of inactivated influenza vaccines in preventing influenza related deaths is 50%--75% in elderly "at risk" groups ([@b27-copd-2-229]; [@b38-copd-2-229]; [@b71-copd-2-229]; [@b53-copd-2-229]). This has been verified by trials in non-institutionalized elderly ([@b110-copd-2-229]) and in elderly with pulmonary or heart diseases ([@b68-copd-2-229]). A large recent study involving over 100,000 people in Taiwan investigating the impact of influenza vaccination on mortality, also demonstrated a 45% reduction in mortality of COPD patients following influenza vaccination and the vaccination was strongly correlated with prevention of death from lung disease in general ([@b111-copd-2-229]).

The assumption that influenza vaccination also appears to protect the vaccinee from all causes of death and not only influenza related deaths, is controversial ([@b96-copd-2-229]) and underlines the difficulty in determining the vaccines effectiveness in large cohort studies. The efficacy of influenza vaccines to prevent serious influenza-related complications in the elderly, can be increased by using both influenza and pneumococcal vaccines and results in a reduction of the number of hospitalizations. Both vaccines are safe and can be co-administered without impairing the antibody response to either vaccine ([@b13-copd-2-229]).

Future challenges in the use of influenza vaccines
==================================================

One of the most critical challenges is to increase the coverage rate of current influenza vaccines among the "at risk" groups, and many developed countries have adopted a policy to increase vaccine uptake. The World Health Assembly has set a goal of annual immunization of at least 75% of people over 65 years of age by 2010 ([@b118-copd-2-229]). In recent years, some countries have had vaccine supply problems, which can only be rectified by increasing vaccine production and encouraging more manufacturers to produce influenza vaccine. This will benefit not only COPD sufferers, but also the general public, as the industry's production capacity will be better placed to meet the considerable demand for vaccine when a new pandemic strikes ([@b124-copd-2-229]). Most influenza vaccine manufacturers use embryonated hens' eggs as the vaccine substrate. Quality-assured eggs cannot be delivered at short notice, as the manufacturers need to plan their production a year in advance. The use of cell culture systems that are more easily scaled up provides more flexibility to accommodate the increasing demand for influenza vaccines and improves pandemic preparedness.

Currently used inactivated influenza vaccines are safe, but the immunogenicity, especially in elderly, is suboptimal. There are a number of different approaches being employed to improve the vaccine efficacy. One option is to return to the use of the more immunogenic whole virus vaccine formulation, which in recent trials has also been shown to have an acceptable reactogenicity profile ([@b45-copd-2-229]) or alternatively, to use a virosomal influenza vaccine, which has the viral surface antigens in a reconstituted viral envelope ([@b50-copd-2-229]). The vaccine immunogenicity can also be increased by adjuvanting the vaccine. This raises new safety issues, especially in patients on medication. However, one of these adjuvants, MF59, has been shown not to cause more side reactions in COPD patients on steroid therapy than healthy subjects ([@b22-copd-2-229]). Several trials have investigated the combined effect of both live and inactivated influenza vaccination, this is however, not considered as a practical routine procedure ([@b43-copd-2-229]). To date, no beneficial effect of vaccination with both live and inactivated influenza vaccines has been found in older patients with COPD ([@b33-copd-2-229]; [@b32-copd-2-229]).

Conclusion
==========

Influenza remains today an important cause of morbidity and mortality, especially in groups with underlying medical conditions like COPD. Inactivated influenza vaccines have been used for many years with hundreds of millions of doses administered and have an excellent safety record in all patients groups. There have been relatively few studies based solely on COPD patients, but nonetheless the conclusion is that there is enough evidence to recommend annual vaccination in this group ([@b84-copd-2-229]; [@b3-copd-2-229]; [@b122-copd-2-229]). Even if the efficacy of current influenza vaccine is not optimal, there is no doubt that its use in COPD sufferers will continue to reduce morbidity, save lives, and reduce health care costs.

![Schematic figure of influenza virus. On the surface of the virus there are three viral proteins, haemagglutinin (HA), neuraminidase (NA) and the matrix 2 protein (M2). Underlining the viral envelope is the matrix 1 protein (M1), the nucleoprotein (NP) encapsidates the genome segments with one complex of the polymerase attached (PB1, PB2 and PA). The non-structural protein 2 (NS2) is also contained in the virion in low numbers.](copd-2-229f1){#f1-copd-2-229}

![A simplified overview of the ecology of influenza A virus. The subtypes that have been detected in each species are shown and the subtypes marked in bold are the highly pathogenic avian influenza subtypes that have caused illness in humans. The main reservoir of influenza A viruses is waterfowl, which may carry highly pathogenic subtypes of influenza without visible illness. The H5N1 has also been detected in domestic cats, however, little is known about their role in H5N1 epidemiology. Currently, we do not have enough knowledge about the importance of migratory birds in the spread of influenza virus (hence the question mark). Interested readers can consult the reviews by Webster et al 1992 or Murphy et al 1996 for further information.](copd-2-229f2){#f2-copd-2-229}

###### 

Influenza A proteins

  **Protein**        **Function**
  ------------------ ---------------------------------------------------------------------------------------------------------------
  HA                 Receptor binding and release of viral genome. Most important antigenic protein. Trimeric structure.
  NA                 Second most important antigenic determinant. Tetrameric enzymatic protein and target for antiviral treatment.
  M2                 Tetrameric H+ ion channel and target for antiviral treatment
  PB1, PB2, PA       Viral polymerase complex
  NP                 Nucleoprotein
  M1                 Structural matrix protein
  NS1, NS2, PB1-F2   Regulatory proteins and RNA transport

###### 

Target groups for vaccination ([@b118-copd-2-229])

  --- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1   Residents of institutions for the elderly or the disabled;
  2   Elderly non-institutionalised individuals with 1 or more of the following chronic conditions, chronic cardiovascular, pulmonary, metabolic or renal disease, or who are immunocompromised;
  3   Other individuals (adults and children aged \>6 months) in the community who have chronic cardiovascular, pulmonary, metabolic or renal disease, or are immunocompromised;
  4   Individuals who are above a nationally defined age limit irrespective of their medical risk status (most countries define the limit of age \>65 years);
  5   Other groups defined on the basis of national data such as those with frequent contact with high-risk persons, health care workers, pregnant women and children 6--23 months old.
  --- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

The efficacy of influenza vaccine in different population groups from representative studies

                                             **Serum HI**   **Laboratory confirmed influenza**   **Hospitalization P&I**   **Death**   **References**
  ------------------------------------------ -------------- ------------------------------------ ------------------------- ----------- ----------------------------------------------------------------------------
  Adults                                     83--90%        73--78%                                                                    [@b5-copd-2-229]
  Elderly, no other risk                     37--86%        30--81%                              33%                       50--75%     [@b35-copd-2-229], [@b27-copd-2-229],[@b110-copd-2-229], [@b61-copd-2-229]
  Elderly, institution and non-institution                  53%                                  50%                       68%         [@b38-copd-2-229]
  Elderly, chronic lung diseases                                                                 52%                       45--70%     [@b69-copd-2-229]
  COPD patients                              45--87%                                                                       45%         Wang 2006, [@b122-copd-2-229]
